A multicentric study to correlate severity of disease and vaccine in COVID-19 pandemic
Ain-Shams Journal of Anesthesiology volume 14, Article number: 67 (2022)
The purpose of the study was to find out correlation between severity of disease and vaccine in COVID-19 pandemic. Primary objective was to know occurrence of post-vaccination breakthrough infections in hospitalized patients and secondary objective was to know of COVID-19 vaccine to prevent severe infection, morbidity, and mortality of patients. This retrospective observational multicentric study included 325 confirmed COVID-19 patients on NRBM/BIPAP/ventilator admitted in high dependency unit (HDU)/intensive care unit (ICU) were divided into based on severity of symptoms and vaccination status. We included adult patients having positive RTPCR (reverse transcription polymerase chain reaction) COVID-19 test/high-resolution computed tomography scan (HRCT) thorax suggestive of COVID-19 pneumonia. Patients who developed adverse reaction post-vaccination, pregnant patient, and lactating mother were excluded from the study.
Total 325 confirmed COVID-19-positive patients were studied. Statistical analysis with SPSS version 26 and data were analyzed by chi-square test and P value < 0.05 were considered as significant. Total duration of hospital stay was less in vaccinated patients compared to non-vaccinated patients. Oxygen requirement was also less in vaccinated patients. Vaccinated patients developed less severe infection than non-vaccinated patients.
COVID-19 vaccination is very effective against severity of disease. It reduces hospitalization, oxygen requirement, and mortality.
We have observed 26.8 million confirmed COVID-19 cases with approximately 3.04 Lakhs deaths so far in India starting from the time of COVID-19 (Mathieu et al. 2021). In 1918, Spanish flue attacked young adults and created havoc due to secondary bacterial infection (Liang et al. 2021). In 1930, it was established that causative agent was virus but not bacteria and it took several years to get effective vaccine against it (Dahl 2018).
However, the risk of severe disease due to delta variant virus infection after vaccination remains very low (Explanation about the effectiveness of the vaccine for coronavirus 2021; Musser et al. 2021). There are some other studies also in favor of low viral load if infection occurs after vaccination as compared to unvaccinated individuals (Edara et al. 2021; Levine-Tiefenbrun et al. 2021). The purpose of this multicentric study was that to correlate severity of disease and vaccine in COVID-19 pandemic. The primary objective of the study was to know incidence of post-vaccination breakthrough infection in hospitalized patients and secondary objective was to know the efficacy of COVID-19 vaccine in prevention of severe infection and death.
This retrospective observational multicentric study was conducted from April to July 2021 at two centers in Ahmedabad, Gujarat. The study was approved by the Institutional Ethics Committee and registered with the Clinical Trials Registry of the India (CTRI/2021/12/038722) from center 1 and center 2. After obtaining telephonic consent, mild, moderate, and severe COVID illness patients forming the study population were recruited by purposive sampling method as per their need for NRBM/BIPAP/ventilator/oxygen therapy.
The inclusion criteria were adult patients having COVID-19 RTPCR (reverse transcription polymerase chain reaction) positive/HRCT (high-resolution computed tomography scan) thorax suggestive of COVID-19 patients developing adverse reaction post-vaccination, pediatrics age group, pregnancy, and lactating mother were excluded from the study.
In COVID Opd room, we received confirmed COVID-positive either with RTPCR (by reverse transcriptase polymerase chain reaction) or HRCT thorax.
Patients had complain of the fever, headache, cold, weakness, loss of taste, and smell as per ICMR guidelines. Patients had symptoms like breathlessness, decreased oxygen saturation, increased heart rate, decreased effort tolerance, and increased work of breathing.
Patients were examined by their effort tolerance, breath holding time, 6-min walk test, and oxygen saturation, and they were admitted at designated concerned COVID areas of ward, HDU, and ICU. All the patients were segregated as per their oxygen requirement.
Detailed vaccination history including date of first dose, second dose, type of vaccine administered, any allergic reaction to vaccine were taken. History of co-morbid condition like diabetes mellitus, hypertension, chronic kidney disease, and tuberculosis was also taken.
Following parameters were observed during study:
Mild symptoms versus first, second, and no dose of vaccine
Severe symptoms versus first, second, and no dose of vaccine
Mode of oxygen therapy versus first, second, and no dose of vaccine
Length of hospital stay, discharge, and mortality versus first, second, and no dose of vaccine
The data was collected both qualitative and quantitative method and analyzed in IBPM SESS software version 20. All the table contents were calculated by using chi-square test. Inference was based on p value. Value of p < 0.05 were considered significant and p < 0.001 suggestive of the highly significant (Tables 1, 2, 3, and 4).
With recent developments in medical science and technology and road map created by vaccines for SARS Cov-1 and Middle East respiratory syndrome corona virus (MERS COV), we got vaccine against COVID-19 in January 2021 which is less than a year after declaration of COVID-19 as pandemic by World Health Organization (WHO) (Hindu 2021). Vaccines approved in India were COVISHIELD (Serum Institute of India), COVAXIN (Bharat Biotech/ICMR/NIV), and SPUTNIK V (Drug Controller General of India (Center for Disease Control and Prevention 2020). These vaccines have provided immunity against disease severity along with associated complications and mortality, which had threatened us mentally, physically, and economically also.
Three vaccine being used in India (COVISHIELD, COVAXIN, SPUTNIK V) have been authorized to be used only in a population of more than 18 years of age. No vaccine is superior to the other and administration must be done depending on the availability (Chauhan 2021). In our institutes, only COVISHIELD vaccine was available so that all the patients had taken this vaccine at that time.
In this retrospective study, after 1st dose of vaccine out of 325 confirmed COVID-positive patients, 108 patient had presented with dry cough, while patient who had not taking single dose of vaccine 177 where suffer from dry cough. After 1st dose of vaccine, 60 patient had present with fever, while patient who had not taking single dose of vaccine 171 where suffer from fever. After 1st dose of vaccine, 30 patient had present with weakness, while patient who had not taking single dose of vaccine 102 suffered from weakness. P value of this mild symptoms verses vaccine was < 0.04 suggestive of the significant.
After 1st dose of vaccine 37, 19 patient had present with severe symptoms of breathlessness and increase respiratory rate while patient who had not taking single dose of vaccine 144, 97 respectively, P value of severe symptoms verses vaccine was < 0.04 suggestive of significant. Any person infected with COVID-19 virus can develop a clinical course of COVID-19. However, it is reported that the most severe symptoms such as respiratory failure in older man with co-morbidities condition (Chen et al. 2020). Children and young people mostly showed a mild presentation of the disease (Xu et al. 2020).
After 1st dose of vaccine 10, 12 patient had needed simple mask, and NRBM mask while patient who had not taking single dose of vaccine 59, 40 needed respectively. Also, after 1st dose of vaccine 36, 7 patients had needed BIPAP and ventilator support while patient who had not taking a single dose of vaccine 95, 36 needed support respectively. P wave of the mode of oxygen therapy verses vaccine was < 0.003 suggestive of highly significant.
According to the analysis done by ICMR, of the 9.3 million who received the first dose of COVAXIN, only 4,208 tested positive; and of the 1.7 million who received the second dose, 695 tested positive. Similarly, for COVISHIELD, of the 100.3 million who received the first dose, 17,145 tested positive; and of the 15 million who got the second dose, 5014 tested positive. This translates to only around 2–4 cases per 10,000 people vaccinated (Joint Statement from the International Coalition of Medicines Regulatory Authorities and World Health Organization n.d.).
Alyson Cavanaugh et al. reported that 46 of the 199 people at the care home were infected during the outbreak at the US Center for Disease Control and Prevention. They estimated that the vaccine was effective and preventing COVID-19 infection, who had past more than 2 weeks of second dose. The dose of vaccine were even more effective at preventing hospitalization (Cavanaugh et al. 2021).
In COVID-19 vaccination, there was 95% efficacy against disease could reduce future attack rate, hospitalization, and death (Moghadas et al. 2021). It was also found that positive cases after the second dose from COVISHILD were 0.3% and 0.04% for COVAXIN, which strongly suggest that people must get vaccinated and not postponed it. These vaccines were disease-modifying vaccines. After both dose were administered, antibody develops and chances of infections decreased (Xu et al. 2020). R J Haris et al. also reported that single dose of the COVID-19 vaccine either Pfizer or Astrazenaca cuts a person’s risk of transmitting SARS-COV2 to their closest contact by as much as half. An analysis of more than 365,000 households in the UK. Although the vaccine have been shown to reduce COVID-19 symptoms and serious illness, their ability to prevent corona virus transmission has been unclear (Haris et al. 2021).
M. G. Thompson et al. noticed that full immunization was 90% effective protecting people against infection and a single dose was 80% effective but researchers caution that because every few participant became infected after vaccination, it is difficult to state the vaccines effectiveness against infection with high precision (Thompson et al. 2021).
Since there was no guarantee of any vaccine being 100% effective, we expect COVID infection in some individuals even after full vaccination. In many countries, there was higher rate of breakthrough infection with delta dominant variant.
This study showed that COVID-19 vaccination is very effective against severity of disease. It is thus imperative for healthcare workers to educate, spread awareness, quote authentic data, motivate, communicate, and bring clarity in the minds of all who are doubting this process of vaccination. Along with this main preventing measure of S-sanitation, M-mask wearing, and S-social distancing is the only way forward to save us from the catastrophe of corona virus infection.
Availability of data and materials
The dataset during the current study are available from the corresponding author on reasonable request.
Severe acute respiratory syndrome
Arterial blood gas analysis
High dependency unit
Intensive care unit
Reverse transcription polymerase chain reaction
High-resolution computed tomography
Cavanaugh AM, et al. (2021) COVID research: a year of scientific milestones. Nature. 2021. https://doi.org/10.1038/d41586-020-00502-w
Center for Disease Control and Prevention (2020) Different COVID-19 vaccines Available,at: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines.html December 31, 2020).
Chauhan M (2021) COVID 19 vaccination - a must to end the pandamic. Indian J Clin Anaesthesia 8(2):152–154
Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 395(10223):507–513. https://doi.org/10.1016/S0140-6736(20)30211-7 Epub 2020 Jan 30. PMID: 32007143; PMCID: PMC7135076
Karie Young Dahl (2018) The Spanish influenza pandemic and vaccine development- history of vaccines; September 2018.
Edara VV, Pinsky BA, Suthar MS, et al (2021) Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants. N Engl J Med 385(7):664-666
Explanation about the effectiveness of the vaccine for coronavirus (2021) https://www.gov.il/en/departments/news/06072021-04
R J Haris et al (2021) COVID research: a year of scientific milestones https://90.nature.com/3esiuli,2021
The Hindu. (2021) “World’s largest vaccination programme begins in India on January 16th” 15 January 2021, Retrieved 16 January 2021.
Joint Statement from the International Coalition of Medicines Regulatory Authorities and World Health Organization: How COVID-19 vaccines are regulated for safety and effectiveness. Available from http://www.icmrahttp://www.icmra.info.
Levine-Tiefenbrun M, Yelin I, Katz R et al (2021) Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine. Nat Med 27:790
Liang ST, Liang LT, Rosen JM (2021) COVID-19: a comparison to the influenza and how we can defeat it. Postgrad Med J 97(1147):273–274. https://doi.org/10.1136/postgradmedj-2020-139070
Mathieu E, Ritchie H, Ortiz-Ospina E et al (2021) A global database of COVID-19 vaccinations. Nat Hum Behav. https://doi.org/10.1038/s41562-021-01122-8
Moghadas SM, Vilches TN, Zhang K et al (2021) The impact of vaccination on COVID-19 outbreaks in the United States. medRxiv:2020.11.27.20240051. Preprint. Published 2021 Jan 2. https://doi.org/10.1101/2020.11.27.20240051
Musser JM, Christensen PA, Olsemn RJ, et al.(2021) Delta variants of SARS-CoV-2 cause significantly increased vaccine breakthrough COVID-19 cases in Houston, Texas, https://www.medrxiv.org/content/10.1101/2021.07.19.21260808v1
Thompson MG, Burgess JL, Naleway AL, et al (2021) Interim estimates of vaccine effectiveness of BNT162b2 and mRNA-1273 COVID-19 vaccines in preventing SARS-CoV-2 infection among health care personnel, first responders, and other essential and frontline workers — Eight U.S. Locations, December 2020–March 2021. MMWR Morb Mortal Wkly Rep 70:495–500
Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ et al (2020) (2020) Clinical and computed tomographic imaging features of Novel Coronavirus Pneumonia caused by SARS-CoV-2. J Infect 80:394–400. https://doi.org/10.1016/j.jinf.2020.02.017 PMID: 32109443; PMCID:PMC7102535
We are thankful to Director Dr. Kirti M Patel, Dean Dr. Yogendra Modi, Medical superintendent Dr. Bharat Ghodadra, CEO Col Dr. Sunilkumar Rao, and also very thankful to our statistician Mr. Vasu Rathod, Department of Community Medicine.
There was no funding and financial support for this study.
Consent of publication
Ethics approval and consent to participate
We have taken ethical approval from both the center name as (1) Institutional Ethics Committee, GCS Medical College Hospital and Research Centre and Number is GCSMC/EC/Research project/APPROVAL 2021/ 304) (2) The Gujarat Cancer and Research Institute Ethical Committee and number is IRC/2021/P 75. We took informed written consent from adult patients and telephonic consent from relatives in this multicentric study (there was no need for consent from parent or legal guardian as pediatric patients were excluded from this study).
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Patel, A.R., Solanki, R.N., Channwal, H.S. et al. A multicentric study to correlate severity of disease and vaccine in COVID-19 pandemic. Ain-Shams J Anesthesiol 14, 67 (2022). https://doi.org/10.1186/s42077-022-00266-7
- COVID-19 vaccine
- Severity of disease